Jounce Therapeutics

Head of Investor Relations and Corporate Communications

Job ID
2021-1255
Category
Business Development
Job Location
US-MA-Cambridge

Role / Responsibilities

This individual will report to the Chief Financial Officer and work closely with the executive team to
establish and implement a successful Investor Relations strategy that articulates and supports the
Company's business and scientific objectives to the investment community and other external audiences
including the scientific community. They will also manage all external communications, including media and public relations (news and editorial coverage, press releases and articles); financial communications, strategic executive
communications; and Company website communications. Will act as a Company spokesperson,
promoting, enhancing, and projecting the organization's vision, brand and reputation to external
stakeholders, with a primary focus on analysts and investors, and build new and manage existing
relationships with the investment community and other outside influencers.

  • Continue to develop Jounce’s investor relations program to ensure a consistent, timely flow of
    information about Jounce to the investment communities and Company shareholders. Establish and
    maintain excellent relations with institutional investors, key retail investors and analysts
  • Understand the science, technology, pipeline and business strategy sufficiently to identify issues and
    effectively communicate with investors
  • Partner with the CEO, CMO and CFO to lead and manage the Company's participation on quarterly
    earnings calls, investment conference calls and in-house meetings, road shows, analyst days, and one-on-one meetings
  • Develop relationships and maintain regular communication with individual investors, covering analysts
    and select buy-side contacts to provide up to date information about events and market trends affecting
    the Company, with the goal of communicating our long-term vision
  • Manage the Company's corporate communications via the Company website, social media channels, etc. Update
    and continuously improve the corporate website and social media efforts ensuring that key messages
    and communications are consistent
  • Lead strategic communications development, including, developing communications plan to take
    advantage of key Company milestones, preparing press releases, presentation decks, and earnings
    releases, creating management Q&As, conference call scripts, and business descriptions/other
    information for securities filings, and the Company website
  • Serve as a primary person to handle incoming inquiries from the media and investors
  • Establish strong internal relationships and effective communication with supporting business,
    scientific, and medical leadership within the organization
  • Manage an external set of advisors to successfully meet group objectives
  • Person should be comfortable with being hands-on and operating within a lean budget

Qualifications

  • Bachelor's degree required; MBA preferred
  • 10+ years of professional level experience with a minimum of 8 years of experience in investor relations, corporate communications, and related areas
  • A minimum of 5 years of investor relations experience in the biotech/pharmaceutical industry, speaking and presenting to investors and analysts
  • Demonstrated experience and leadership in managing a comprehensive strategic communications programs to advance the organizations vision, mission, values, and strategic objectives
  • Experience in delivering clear consistent messaging of scientific and clinical concepts across multiple stakeholders / audiences
  • Proven track record of developing a positive, long-term relationship with the investment community
  • Experience with, and a working knowledge of SEC disclosure requirements, shareholder/analyst communications practices, and preparing investor presentations and events
  • Demonstrated experience to lead and influence within a matrixed environment, including with senior management
  • Experience in managing and overseeing contract IR/PR agencies and vendors
  • Computer skills are a must (particularly PowerPoint, Excel and Word)

Statement

Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs. We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S.

Company Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.

Options

Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
Share on your newsfeed